trametinib Archives - Drugs in Context

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti

Article Type

Review

Published

02 May 2023

This review aims to offer a comprehensive update about available therapeutic options for patients with NSCLC harbouring BRAF mutations to guide the physician in the choice of treatment strategies.

Agents to treat BRAF-mutant lung cancer

Jean G Bustamante Alvarez MD, MS, Gregory A Otterson MD

Article Type

Review

Published

13 Mar 2019

Evaluating cost benefits of combination therapies for advanced melanoma

Ivar S Jensen, Emily Zacherle, Christopher M Blanchette, Jie Zhang, Wes Yin

Article Type

Original Research

Published

15 Jul 2016

The model presented in this study was used to analyze the clinical and economic benefit of using combination therapies in advanced melanoma patients with the BRAF V600 mutation. The analysis suggests dabrafenib + trametinib therapy is associated with less patient time and lower costs relative to nivolumab + ipilimumab to gain similar progression-free survival and overall response rate benefits.